Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial

Facial angiofibromas, composed of fibrous tissue and blood vessels appearing on the face, are closely associated with tuberous sclerosis complex. Historically, oral rapamycin, a mammalian target of the rapamycin inhibitor of cell proliferation, has been used to treat visceral tuberous sclerosis–rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheless, Margaret C., Takwi, Apana A., Almoazen, Hassan, Wheless, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/
https://www.ncbi.nlm.nih.gov/pubmed/31259191
http://dx.doi.org/10.1177/2329048X19835047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/
https://www.ncbi.nlm.nih.gov/pubmed/31259191
http://dx.doi.org/10.1177/2329048X19835047

Ejemplares similares